Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 2007 Aug;49(2):196-8
Date
04/10/2007Pubmed ID
17417796DOI
10.1002/pbc.21182Scopus ID
2-s2.0-34447256148 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
The role of tandem high-dose chemotherapy (HDC) with autologous peripheral hematopoietic progenitor cell rescue (APHPCR) in patients with Ewing Family Tumors (EFT) is controversial. We initiated treatment for eight consecutive patients with high-risk EFT with HDC and APHPCR from 1992 to 2003. There were no treatment related deaths. Four patients remain in complete remission, including three who did not undergo local therapy to bone at either the primary or metastatic sites. Our experience has shown that treatment of EFT patients with tandem HDC with APHPCR may benefit a subgroup of high-risk patients in whom optimal local therapy is not possible.
Author List
Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel MAuthor
Michael James Burke MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Antineoplastic Combined Chemotherapy Protocols
Bone Neoplasms
Child
Combined Modality Therapy
Cyclophosphamide
Doxorubicin
Drug Administration Schedule
Etoposide
Feasibility Studies
Female
Humans
Ifosfamide
Lung Neoplasms
Male
Mesna
Neoadjuvant Therapy
Neuroectodermal Tumors, Primitive
Pelvic Bones
Peripheral Blood Stem Cell Transplantation
Remission Induction
Risk
Sarcoma, Ewing
Scapula
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Vincristine
